After failure of an initial drainage implant to control IOP, a sequential tube had a high initial rate of success but a relatively high likelihood of long-term failure, generally after 6 years. Eyes that received CPC tended to fail earlier, often within the first year, but had relatively few late failures.

No abstract

To determine if sequential treatment with Bevacizumab (Avastin), a monoclonal, VEGF antibody that blocks angiogenesis; Saratin, a 12 kD polypeptide with anti-inflammatory and anti-thrombotic properties; and Ilomastat, a matrix metalloproteinase (MMP) inhibitor, prolongs bleb life following glaucoma filtration surgery (GFS) in a rabbit model. Thirty-two New Zealand White rabbits (eight rabbits per group) underwent GFS in the left eye. Group 1 received a perioperative injection of both Saratin and Bevacizumab, and later, subconjuctival injections of Ilomastat on days 8 and 15. Group 2 received only Saratin perioperatively, and also received Ilomastat injections on days 8 and 15. Group 3, the negative control, received a single perioperative injection of Balanced Saline Solution (BSS) along with post-operative BSS injections on days 8 and 15. Group 4, the positive control, received topical treatment with Mitomycin-C (MMC) at the time of surgery with no further treatment. Blebs were evaluated by an observer masked to treatment every third day. Histology was obtained on two eyes in each group on post-op day twelve as well as all eyes following bleb failure. Eyes in group 1 had a mean bleb survival time of 29 ± 2.7 days, whereas those in group 2 that received the experimental treatment without Bevacizumab had a mean survival time of 25.5 ± 2.7 days. An ANOVA test showed that the Saratin/Ilomastat/Bevacizumab group demonstrated a significant prolongation of bleb survival compared to the BSS control—mean survival time of 19.7 ±2.7 days—(p = 0.0252) and was not significantly different from the MMC positive control group (p = 0.4238)—mean survival time of 32.5 ± 3.3. From tissue histology at day 12, the four different groups showed marked differences in the cellularity and capsule fibrosis. The MMC eyes showed minimal cellularity, were avascular and had minimal fibrous tissue. BSS group showed high cellularity, moderate to high fibrosis, and thicker and more defined capsules than either of the treatment groups and the positive control. Both the Saratin/Ilomastat/Bevacizumab and Saratin/Ilomastat only eyes showed moderate cellularity with minimal fibrosis, with less cellularity and fibrosis present in the triple treatment group. Sequential therapy with multiple agents, including Bevacizumab, prolonged bleb function following GFS in the rabbit model and were significantly better than the negative BSS control. The experimental group did not show the same surface tissue histological thinning and side effects associated with MMC treatment.

Purpose To compare the accuracy and speed of using the computerized MatchedFlicker® software program to evaluate glaucomatous optic disc change against the traditional gold-standard of manually examining stereoscopic disc photographs. Design A prospective evaluation of diagnostic technology. Methods Two resident ophthalmologists and one glaucoma fellow at the University of Florida independently evaluated 140 image-pairs from 100 glaucomatous/ocular hypertensive patient eyes using a handheld stereo-viewer and the MatchedFlicker® program. Fifty had progression to glaucoma as determined by the OHTS Optic Disc Reading Group and the OHTS end-point committee in the Ocular Hypertension Treatment Study (OHTS), and fifty more had photos taken a few minutes apart which were negative controls with no progression. Twenty photo-pairs from each group were duplicated to determine reviewer variability. Photos were examined in alternating blocks of 70 photo pairs for each method, with the starting viewing method randomized. Reviewer accuracy and time to review for each method were measured. Results Using the handheld stereo-viewer, the reviewers correctly identified progression or non-progression in 76.0% of the slide-pairs. Using the MatchedFlicker® software 87.6% were correctly identified (p=0.011). Evaluator speed averaged 34.1 seconds per image-pair with the stereo-viewer verses 24.9 seconds with the MatchedFlicker® program (p=0.044). Overall, Flicker was significantly more specific but less sensitive than stereo slides. Trainees appeared more reluctant to identify glaucoma progression for slides than Flicker. For the two less experienced trainees Flicker was significantly more accurate. Conclusion The MatchedFlicker® software had a greater accuracy and was quicker to perform than using a handheld stereoscopic viewer.